Management of Pancytopenia in Elderly Patients

Initial Assessment and Treatment

The American College of Physicians recommends immediate medication review to identify and discontinue myelotoxic agents, followed by supportive care measures and etiology-specific therapy, with particular attention to avoiding refeeding syndrome when nutritional deficiencies are present 1
Immediately review and discontinue all potentially myelotoxic medications, including azathioprine, anticoagulants, antibiotics, and antihypertensives, to prevent further bone marrow suppression 1, 2
Obtain complete blood count with differential, reticulocyte count, peripheral blood smear, and comprehensive metabolic panel including renal and hepatic function to guide further management 1
Before initiating any nutritional support, assess serum phosphate, magnesium, and potassium levels to prevent refeeding syndrome, which carries up to 20% mortality risk in elderly patients 1

For myelodysplastic syndrome (MDS), the European Society for Medical Oncology recommends azacitidine (at least 6 cycles) as the standard treatment for higher-risk MDS in elderly patients >65-70 years, with supportive care including RBC transfusions and antibiotics for frail patients 4
Hypomethylating agents (HMAs) yield RBC transfusion independence in 30-40% of patients with lower-risk MDS and are effective for other cytopenias 4, 5
Anti-thymocyte globulin (ATG) with or without cyclosporin A produces responses in 25-40% of patients with lower-risk MDS, but works best in relatively young patients (<65 years) with specific features (normal karyotype, no excess blasts, marrow hypocellularity) 4, 5, 3

Provide RBC transfusions for symptomatic anemia with appropriate chelation therapy for transfusion-dependent patients, as recommended by the American Society of Hematology 4, 3
Platelet transfusions should be given for severe thrombocytopenia with bleeding risk, according to the American College of Physicians 3
Establish more frequent hematological monitoring specific to elderly patients, including weekly complete blood counts to assess response to therapy, as suggested by the European Society for Medical Oncology 1, 3

Start nutritional support early but increase gradually over the first 72 hours to avoid refeeding syndrome, as recommended by the American Geriatrics Society 1
Monitor phosphate, magnesium, potassium, and thiamine levels closely during the first 3 days of repletion, according to the European Society for Clinical Nutrition and Metabolism 1
Provide folate and B vitamin supplementation as essential components of management, as suggested by the American College of Physicians 3

Account for age-related physiological changes including insulin resistance and impaired glucose tolerance when managing elderly pancytopenic patients, as recommended by the American Geriatrics Society 1
Consider increased toxicity risk with chemotherapy regimens, particularly febrile neutropenia and sepsis-related deaths in patients with poor performance status, according to the European Society for Medical Oncology 6
For frail elderly patients, supportive care alone may be the most appropriate approach rather than aggressive disease-modifying therapy, as suggested by the American Society of Hematology 4, 7